{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:31:26Z","timestamp":1778776286567,"version":"3.51.4"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement","award":["ALFGBG-430711"],"award-info":[{"award-number":["ALFGBG-430711"]}]},{"name":"grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement","award":["ALFGBG-698991"],"award-info":[{"award-number":["ALFGBG-698991"]}]},{"name":"Grant from the Gothenburg Society of Medicine"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2019,11,22]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                  <jats:title>Aims\/hypothesis<\/jats:title>\n                  <jats:p>Dyslipidemia is an important modifiable risk factor and lipid-lowering treatment (LLT) is essential to reduce the risk of cardiovascular disease (CVD). Studies in type 2 diabetes indicate that low adherence to statin therapy is a barrier to reach full protective potential, and less is known in type 1 diabetes (T1D). The aim was to assess\u202frisk of CVD by adherence and nonpersistence to LLT in T1D.\u202f<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>A population-based study with a retrospective longitudinal design was conducted between 2006 and 2010, with follow-up until December 2013. In total, 6192 adult individuals with\u202fT1D, initiating\u202fLLT\u202fbetween 2006 and 2010, were included.\u202fInformation on LLT, socioeconomic characteristics, comorbidities and cardiovascular events\u202fwere collected. After 18 months, refill adherence was estimated by calculating medication possession ratio (MPR). Nonpersistence was defined as being without medicines on hand for at least 180 days. Individuals were thereafter\u202ffollowed until\u202fCVD, death\u202for\u202fend of follow-up in December 2013. Cox regression analyses were performed to assess adherence level and nonpersistence of LLT as predictor of\u202fCVD. Analyses were\u202fadjusted for cardiovascular risk factors and\u202fsocioeconomic status.\u202f\u202f<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean MPR\u202fwas 72%, 52% of the participants had an MPR above 80% and 27% discontinued LLT. There were 637\u202fnonfatal\u202fand\u202f58 fatal CVD\u202fevents, mean follow-up 3.6 and 3.9 years, respectively. MPR above 80% was associated with reduced risk for nonfatal CVD compared with lower MPR, HR 0.78 (95% CI 0.65 to 0.93)). For fatal CVD, results indicated a negative effect of high adherence but the association did not reach statistical significance, HR 1.96 (0.96 to 4.01). Individuals discontinuing LLT had higher risk of nonfatal CVD, HR 1.43 (95% CI 1.18 to 1.73).\u202f<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions\/Interpretation<\/jats:title>\n                  <jats:p>In T1D, the risk for nonfatal CVD was lower among individuals with high adherence and higher among those discontinuing LLT within 18 months. It is important to evaluate and\u202femphasize adherence to\u202fprescribed\u202fLLT\u202fat clinical visits to achieve treatment goals and reduce the risk of CVD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2019-000719","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T05:45:11Z","timestamp":1578980711000},"page":"e000719","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-8952","authenticated-orcid":false,"given":"Christel","family":"Hero","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-9587","authenticated-orcid":false,"given":"Sofia Axia","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Franz\u00e9n","sequence":"additional","affiliation":[{"name":"National Diabetes Register, Centre of Registers, V\u00e4stra G\u00f6taland, Gothenburg, Sweden"},{"name":"Health Metrics Unit, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Marie","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"National Diabetes Register, Centre of Registers, V\u00e4stra G\u00f6taland, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervete","family":"Miftaraj","sequence":"additional","affiliation":[{"name":"National Diabetes Register, Centre of Registers, V\u00e4stra G\u00f6taland, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soffia","family":"Gudbj\u00f6rnsdottir","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"National Diabetes Register, Centre of Registers, V\u00e4stra G\u00f6taland, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Andersson Sundell","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Medical Evidence and Observational Research Centre, AstraZeneca AB, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Eliasson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-4707","authenticated-orcid":false,"given":"Katarina","family":"Eeg-Olofsson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"2025073111491314000_8.1.e000719.1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91086-1"},{"key":"2025073111491314000_8.1.e000719.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16425"},{"key":"2025073111491314000_8.1.e000719.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31506-X"},{"key":"2025073111491314000_8.1.e000719.4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.530"},{"key":"2025073111491314000_8.1.e000719.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"2025073111491314000_8.1.e000719.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2025073111491314000_8.1.e000719.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"2025073111491314000_8.1.e000719.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"2025073111491314000_8.1.e000719.9","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2450"},{"key":"2025073111491314000_8.1.e000719.10","unstructured":"World Health Organization . Adherence to long-term therapies: evidence for action."},{"key":"2025073111491314000_8.1.e000719.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht295"},{"key":"2025073111491314000_8.1.e000719.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005402","article-title":"Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland","volume":"4","author":"Ruokoniemi","year":"2014","journal-title":"BMJ Open"},{"key":"2025073111491314000_8.1.e000719.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.08.026"},{"key":"2025073111491314000_8.1.e000719.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0673-0"},{"key":"2025073111491314000_8.1.e000719.15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pds.3936","article-title":"Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes","volume":"25","author":"Korhonen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025073111491314000_8.1.e000719.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020309","article-title":"Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study","volume":"8","author":"Karlsson","year":"2018","journal-title":"BMJ Open"},{"key":"2025073111491314000_8.1.e000719.17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11739-011-0653-0","article-title":"Use and indications of cholestyramine and bile acid sequestrants","volume":"8","author":"Scaldaferri","year":"2013","journal-title":"Intern Emerg Med"},{"key":"2025073111491314000_8.1.e000719.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2025073111491314000_8.1.e000719.19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2204"},{"key":"2025073111491314000_8.1.e000719.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01630.x"},{"key":"2025073111491314000_8.1.e000719.21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/03007995.2017.1281109","article-title":"A systematic review to assess adherence and persistence with statins","volume":"33","author":"Deshpande","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2025073111491314000_8.1.e000719.22","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/pds.4281","article-title":"Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: a nation-wide register-based study","volume":"26","author":"Karlsson","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025073111491314000_8.1.e000719.23","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0168-8227(14)70732-6","article-title":"Diabetes care--improvement through measurement","volume":"106(Suppl 2)","author":"Eliasson","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073111491314000_8.1.e000719.24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"2025073111491314000_8.1.e000719.25","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025073111491314000_8.1.e000719.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.12.007"},{"key":"2025073111491314000_8.1.e000719.27","unstructured":"Statistics Sweden . Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym). Available: http:\/\/www.scb.se\/lisa-en\/ [Accessed Last accessed Sep 2019]."},{"key":"2025073111491314000_8.1.e000719.28","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"2025073111491314000_8.1.e000719.29","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2025073111491314000_8.1.e000719.30","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000250227.94196.f0"},{"key":"2025073111491314000_8.1.e000719.31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12339"},{"key":"2025073111491314000_8.1.e000719.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"2025073111491314000_8.1.e000719.33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2125.2010.03895.x","article-title":"Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study","volume":"71","author":"Ruokoniemi","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2025073111491314000_8.1.e000719.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0980-z"},{"key":"2025073111491314000_8.1.e000719.35","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.diabres.2008.12.015","article-title":"Persistence with statin therapy in diabetic and non-diabetic persons: a nation-wide register study in 1995-2005 in Finland","volume":"84","author":"Helin-Salmivaara","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073111491314000_8.1.e000719.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0318-9","article-title":"Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort","volume":"15","author":"Bai","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2025073111491314000_8.1.e000719.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02476.x"},{"key":"2025073111491314000_8.1.e000719.38","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-019-1099-z","article-title":"Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis","volume":"18","author":"Toth","year":"2019","journal-title":"Lipids Health Dis"},{"key":"2025073111491314000_8.1.e000719.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.367"},{"key":"2025073111491314000_8.1.e000719.40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacl.2013.03.029","article-title":"Predictors of statin adherence, switching, and discontinuation in the usage survey: understanding statin use in America and gaps in patient Education*","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"key":"2025073111491314000_8.1.e000719.41","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31357-5"},{"key":"2025073111491314000_8.1.e000719.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31075-9"},{"key":"2025073111491314000_8.1.e000719.43","doi-asserted-by":"publisher","DOI":"10.1161\/atv.0000000000000073"},{"key":"2025073111491314000_8.1.e000719.44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14740338.2018.1458837","article-title":"Preventable statin adverse reactions and therapy discontinuation. what can we learn from the spontaneous reporting system?","volume":"17","author":"Sessa","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2025073111491314000_8.1.e000719.45","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S009"},{"key":"2025073111491314000_8.1.e000719.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"2025073111491314000_8.1.e000719.47","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2101"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2019-000719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:49:19Z","timestamp":1753987759000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2019-000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,13]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bmjdrc-2019-000719"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2019-000719","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}